Search results
Showing 106 to 120 of 204 results for lymphoma
Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID977]
Discontinued Reference number: GID-TA11238
Discontinued Reference number: GID-TA10308
This quality standard covers interventions to improve the uptake of HIV testing among people who may have undiagnosed HIV. It focuses on increasing testing to reduce undiagnosed infection in people at increased risk of exposure. It describes high-quality care in priority areas for improvement.
View quality statements for QS157Show all sections
Sections for QS157
- Quality statements
- Quality statement 1: Hospitals in areas of high and extremely high HIV prevalence
- Quality statement 2: General practice in areas of high and extremely high HIV prevalence
- Quality statement 3: HIV indicator conditions
- Quality statement 4: Regular HIV testing
- Quality statement 5: People who may have been exposed to HIV
- Update information
- About this quality standard
Awaiting development Reference number: GID-TA11705 Expected publication date: TBC
Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]
Discontinued Reference number: GID-TAG278
Awaiting development Reference number: GID-TA11867 Expected publication date: TBC
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]
Discontinued Reference number: GID-TAG321
Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]
Discontinued Reference number: GID-TAG425
Past technology appraisal appeals and decisions
Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]
Discontinued Reference number: GID-TA10464
Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma [ID997]
Discontinued Reference number: GID-TA10382
Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]
Discontinued Reference number: GID-TAG424
T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]
Discontinued Reference number: GID-TAG433
Awaiting development Reference number: GID-TA11590 Expected publication date: TBC
Awaiting development Reference number: GID-TA11811 Expected publication date: TBC